Why TC Biopharm (TCBP) Stock Is Down Over 60% Today

0.00%

TC Biopharm (Holdings) Plc Sponsored ADR

TCBP

TC Biopharm PLC – ADR (NASDAQ:TCBP) shares are trading lower by 62% to 58 cents during Friday’s session after the company announced the transition from Nasdaq to OTC markets.

What To Know: TC BioPharm a clinical-stage biotech firm, announced that Nasdaq has decided to delist its securities for failing to meet the $1.00 minimum bid price requirement under Rule 5550(a)(2).

The company received notice of this decision on Thursday. TC BioPharm, which focuses on allogeneic gamma-delta T-cell therapies for cancer and other diseases, is now working on an appeal to Nasdaq in an effort to regain compliance.

Read Also: ‘Monster Equity Inflows Say No One Really Believes Trade War,’ Bank Of America’s Hartnett Says

According to data from Benzinga Pro, has a 52-week high of $523.20 and a 52-week low of $0.54.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.